Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 10/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | CCR2 | P41597 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL398570 | 0.85 | ENPP2 (0.50) | PTGS2PTGDR2CYP3A4 | |
| SCHEMBL7089391 | 0.83 | PTGS2 (0.44) | PTGS2PTGDR2CYP3A4TDP1GRIN2B | |
| SCHEMBL22871613 | 0.81 | CYP3A4 (0.57) | CYP3A4TDP1LMNA | |
| SCHEMBL7688313 | 0.81 | MMP2 (0.38) | CYP3A4TDP1 | |
| Hydrochloric Acid SCHEMBL5143704 | 0.79 | CYP3A4 (0.55) | CYP3A4TDP1 | |
| (Chloromethyl)Benzene SCHEMBL304085 | 0.79 | CYP3A4 (0.60) | CYP3A4TDP1LMNA | |
| SCHEMBL15201702 | 0.78 | TP53 (0.50) | CYP3A4TDP1LMNA | |
| SCHEMBL6201046 | 0.76 | TDP1 (0.50) | CYP3A4TDP1LMNA | |
| SCHEMBL9505755 | 0.75 | HTT (0.44) | PTGS2LMNA | |
| SCHEMBL5783635 | 0.75 | CYP3A4 (0.40) | PTGS2CYP3A4TDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030050330-A1 | 4,5-subtstituted imdazolyl compounds for the treatment of inflammation | G.D. SEARLE & CO. | 2003-03-13 | — | — | US | disclosed |
| US-6426360-B1 | ANTIARTHRITIC AGENTS | G D SEARLE & CO. | 2002-07-30 | — | — | US | disclosed |
| EP-0772601-A1 | 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1997-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030050330-A1 | 4,5-subtstituted imdazolyl compounds for the treatment of inflammation | AHR, HACL2, IRAK2 | PTGS2 122/4885PTGDR2 502/4885CYP3A4 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.